Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Celldex is developing targeted therapeutics to address devastating diseases for wh...
Celldex is developing targeted therapeutics to ...
We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-...
We are rapidly translating our specific, effici...
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utiliz...
Protagonist Therapeutics is a clinical stage bi...
Genocea is a biopharmaceutical company developing personalized cancer immunotherap...
Genocea is a biopharmaceutical company developi...
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a specialty clinical-stage pharmaceuti...
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a s...
EyeGate is developing and commercializing products for treating diseases and disor...
EyeGate is developing and commercializing produ...
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...
Spring Bank is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.